VBI Vaccines — World Vaccine Congress 2024
11 slides from VBI Vaccines's conference presentation, Apr 3, 2024

Slide 1: Early Tumor Response Data from the Randomized, Controlled Phase 2b Trial of VBI-1901
UG ~ Vv B | Zmy VACCINES Zin ACTIVATING THE POWER WITHIN Early Tumor Response Data from the Randomized, Controlled Phase 2b Trial of VBI- 1901 for the Treatment of Recurrent Glioblastoma World Vaccine Congress 2024 April 3, 2024

Slide 2: Forward-Looking & Safe Harbor Statements
Forward-Looking & Safe Harbor Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-look

Slide 3: New Approaches are Required to Target Glioblastoma
New Approaches are Required to Target Glioblastoma Glioblastoma is among the most common and aggressive malignant brain tumors Given Medical Need, Approved Therapies Needed Only to Demonstrate Some Survival Benefits Universally Fatal Brain Cancer ‘Over 30,000 new glioblastoma (GBM) diagnoses per yea

Slide 4: Antigen Selection is Critical to Restimulate Immunity
Antigen Selection is Critical to Restimulate Immunity and Redirect to the Tumor Microenvironment Cancer vaccines have been proven to enhance Checkpoint Inhibitor efficacy when appropriate antigen(s) are targeted Checkpoint Inhibitors + vaccination with poorly immunogenic antigens (gp100) did Checkpo

Slide 5: Cytomegalovirus (CMV) is a Highly Immunogenic Viral Target Present in Over 90% of GBM Tumors
Cytomegalovirus (CMV) is a Highly Immunogenic Viral Target Present in Over 90% of GBM Tumors Using a variety of techniques, multiple labs have confirmed the presence of CMV antigens in GBM tumor samples, but not in adjacent healthy tissue! Immuno-histochemical staining of CMV pp65 antigen in a GBM s

Slide 6: Our Approach to Cancer Vaccines is Differentiated from Historical Attempts to Treat GBM
Our Approach to Cancer Vaccines is Differentiated from Historical Attempts to Treat GBM Shortcomings of Past Cancer | Vaccine Approaches n Previous cancer vaccines have failed in GBM studies due to poorly immunogenic delivery, which lacked: + Inherent potency + Balanced immunity + Breadth VBI's Enve

Slide 7: Design & Objectives: Ongoing Phase 1/2 Study in Recurrent GBM Patients
Design & Objectives : Ongoing Phase 1/2 Study in Recurrent GBM Patients Phase 2a (Part B) : Phase 2b (Part C) : Extension Phase Randomized, Controlled Phase Phase 1 (Part A) Dose-Escalation Phase Study Arm 1: High Dose (n=30) 10.0g + GM-CSF vs. Study Arm 1: Low Dose (n=6) Study Arm 1: High Dose (n=1

Slide 8: Data from Part A & B of Ongoing Phase 1/2 Study
Data from Part A & B of Ongoing Phase 1/2 Study As at August 1, 2023 Based on the below results, U.S. FDA granted Fast Track Designation and Orphan Drug Designation to VBI- 1901 + GM-CSF for the treatment of recurrent GBM patients with first tumor recurrence jor Responses High Dose: Parts A & 8 Dise

Slide 9: Early Tumor Response Data from Part C (Phase 2b) of Ongoing Phase 1/2 Study
Early Tumor Response Data from Part C (Phase 2b) of Ongoing Phase 1/2 Study 17 patients have been randomized and received first dose of treatment as of March 22, 2024 N=8 : Standard-of-Care (SoC) arm (Carmustine or lomustine) N=9: VBI-190] arm ll patients currently evaluable for tumor response asses

Slide 10: Summary and Next Steps for VBI-1901
Summary and Next Steps for VBI-1901 Summary of Part A&B Early Data from Part C Next Steps ~5-month improvement in mOS observed vs. historical standard-of- care (12.9 months vs. 8 months) 12-month O$ : 62.5% (n=10/16) 2 partial tumor responses (PRs) 93% tumor reduction seen in one patient who remaine

Slide 11: VBI Vaccines Inc.
WP =VBI Amy YY Wy 7M A! VBI Vaccines Inc. | www.vbivaccines.com
Source: SEC EDGAR · 8-K filed Apr 3, 2024
More decks from VBI Vaccines Inc.
Investor Presentation (February 2023)41 slides · Feb 28, 2023
Hepatitis B Portfolio Fireside Chat led by Raymond James (February 2023)29 slides · Feb 28, 2023
Investor Presentation (December 2022)37 slides · Dec 27, 2022
Corporate Update (September 2021)11 slides · Sep 29, 2021
Technical Presentation (November 2020)7 slides · Nov 19, 2020
Corporate Update (November 2020)8 slides · Nov 18, 2020